Literature DB >> 29665102

Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.

Jasmohan S Bajaj1, Genta Kakiyama1, Tor Savidge2, Hajime Takei3, Zain A Kassam4, Andrew Fagan1, Edith A Gavis1, William M Pandak1, Hiroshi Nittono3, Phillip B Hylemon1, Prapaporn Boonma2, Anthony Haag2, Douglas M Heuman1, Michael Fuchs1, Binu John1, Masoumeh Sikaroodi5, Patrick M Gillevet5.   

Abstract

Patients with cirrhosis are often exposed to antibiotics that can lead to resistance and fungal overgrowth. The role of fecal microbial transplant (FMT) in restoring gut microbial function is unclear in cirrhosis. In a Food and Drug Administration-monitored phase 1 clinical safety trial, patients with decompensated cirrhosis on standard therapies (lactulose and rifaximin) were randomized to standard-of-care (SOC, no antibiotics/FMT) or 5 days of broad-spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae. Microbial composition (diversity, family-level relative abundances), function (fecal bile acid [BA] deconjugation, 7α-dehydroxylation, short-chain fatty acids [SCFAs]), and correlations between Lachnospiraceae, Ruminococcaceae, and clinical variables were analyzed at baseline, postantibiotics, and 15 days post-FMT. FMT was well tolerated. Postantibiotics, there was a reduced microbial diversity and autochthonous taxa relative abundance. This was associated with an altered fecal SCFA and BA profile. Correlation linkage changes from beneficial at baseline to negative after antibiotics. All of these parameters became statistically similar post-FMT to baseline levels. No changes were seen in the SOC group.
CONCLUSION: In patients with advanced cirrhosis on lactulose and rifaximin, FMT restored antibiotic-associated disruption in microbial diversity and function. (Hepatology 2018; 00:000-000).
© 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29665102     DOI: 10.1002/hep.30037

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

Review 1.  Altered Microbiome in Patients With Cirrhosis and Complications.

Authors:  Chathur Acharya; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2018-08-09       Impact factor: 11.382

2.  Just another crappy commentary: the future of fecal microbiota transplantation.

Authors:  James T Rosenbaum
Journal:  Expert Rev Clin Immunol       Date:  2019-10-08       Impact factor: 4.473

3.  Gut microbiome in liver pathophysiology and cholestatic liver disease.

Authors:  Shengmin Yan; Xiao-Ming Yin
Journal:  Liver Res       Date:  2021-08-08

Review 4.  Promises of microbiome-based therapies.

Authors:  Jasmohan S Bajaj; Siew C Ng; Bernd Schnabl
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

5.  Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis.

Authors:  Jasmohan S Bajaj; Nita Salzman; Chathur Acharya; Hajime Takei; Genta Kakiyama; Andrew Fagan; Melanie B White; Edith A Gavis; Mary L Holtz; Michael Hayward; Hiroshi Nittono; Phillip B Hylemon; I Jane Cox; Roger Williams; Simon D Taylor-Robinson; Richard K Sterling; Scott C Matherly; Michael Fuchs; Hannah Lee; Puneet Puri; R Todd Stravitz; Arun J Sanyal; Lola Ajayi; Adrien Le Guennec; R Andrew Atkinson; Mohammad S Siddiqui; Velimir Luketic; William M Pandak; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  JCI Insight       Date:  2019-12-19

6.  Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis.

Authors:  Jasmohan S Bajaj; Puneeta Tandon; Jacqueline G OʼLeary; Florence Wong; Scott W Biggins; Guadalupe Garcia-Tsao; Patrick S Kamath; Benedict Maliakkal; Michael B Fallon; Jennifer C Lai; Paul J Thuluvath; Hugo E Vargas; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Am J Gastroenterol       Date:  2019-04       Impact factor: 10.864

7.  Fecal Microbiota Transplantation Commonly Failed in Children With Co-Morbidities.

Authors:  Richard Kellermayer; Qinglong Wu; Dorottya Nagy-Szakal; Karen Queliza; Faith D Ihekweazu; Claire E Bocchini; Abria R Magee; Numan Oezguen; Jennifer K Spinler; Emily B Hollister; Robert J Shulman; James Versalovic; Ruth Ann Luna; Tor C Savidge
Journal:  J Pediatr Gastroenterol Nutr       Date:  2022-02-01       Impact factor: 2.839

Review 8.  The microbiota in cirrhosis and its role in hepatic decompensation.

Authors:  Jonel Trebicka; Jane Macnaughtan; Bernd Schnabl; Debbie L Shawcross; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-07       Impact factor: 30.083

Review 9.  The Role of the Microbiome in Liver Cancer.

Authors:  Mar Moreno-Gonzalez; Naiara Beraza
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  Antibiotic-Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant.

Authors:  Benjamin H Mullish; Julie A K McDonald; Mark R Thursz; Julian R Marchesi
Journal:  Hepatology       Date:  2018-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.